Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-PD-1 Antibody (9O437) is an antibody targeting PD-1. Anti-PD-1 Antibody (9O437) can be used in ELISA,IHC,WB.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 50 μL | $208 | 7-10 days | 7-10 days | |
| 100 μL | $349 | 7-10 days | 7-10 days |
| Description | Anti-PD-1 Antibody (9O437) is an antibody targeting PD-1. Anti-PD-1 Antibody (9O437) can be used in ELISA,IHC,WB. |
| Synonyms | SLEB2, PDCD1, PD-1, PD1, CD279 |
| Ig Type | Rabbit IgG |
| Clone | 9O437 |
| Reactivity | Human |
| Verified Activity | 1. Western Blot -Positive WB detected in: MCF-7 whole cell lysate -All lanes: PD1 antibody at 1:2000 -Secondary: Goat polyclonal to rabbit IgG at 1/50000 dilution -Predicted band size: 32 KDa -Observed band size: 32 kDa 2. IHC image of TMAH-00865 diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB. |
| Application | |
| Recommended Dose | WB:1:500-1:5000; IHC:1:50-1:200. |
| Antibody Type | Monoclonal |
| Subcellular Localization | Cell membrane; Single-pass type I membrane protein. |
| Construction | Recombinant Antibody |
| Purification | Affinity-chromatography |
| Appearance | Liquid |
| Formulation | Phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Research Background | Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
| Conjucates | Unconjugated |
| Immunogen | A synthetic peptide: Human PD1 |
| Antigen Species | Human |
| Gene Name | PDCD1 |
| Gene ID | |
| Uniprot ID | |
| Biology Area | Cancer, Cell biology, Immunology |
| Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.